Cargando…
Drug-Induced Liver Injury: Biomarkers, Requirements, Candidates, and Validation
The hepatotoxicity of drugs is the main cause of drug withdrawal from the pharmaceutical market and interruption of the development of new molecules. Biomarkers are useful in several situations. In case of suspected drug-induced liver injury (DILI), biomarkers can be used to confirm liver damage, it...
Autores principales: | Meunier, Lucy, Larrey, Dominique |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6917655/ https://www.ncbi.nlm.nih.gov/pubmed/31920666 http://dx.doi.org/10.3389/fphar.2019.01482 |
Ejemplares similares
-
Immunotherapy and Gene Therapy: New Challenges in the Diagnosis and Management of Drug-Induced Liver Injury
por: Delire, Bénédicte, et al.
Publicado: (2022) -
Drug-Induced Liver Injury and COVID-19 Infection: The Rules Remain the Same
por: Olry, Alexandre, et al.
Publicado: (2020) -
Hepatotoxicity of Drugs Used in Multiple Sclerosis, Diagnostic Challenge, and the Role of HLA Genotype Susceptibility
por: Meunier, Lucy, et al.
Publicado: (2023) -
Molecular Biomarkers in Drug-Induced Liver Injury: Challenges and Future Perspectives
por: Fu, Siyu, et al.
Publicado: (2020) -
The Immunological Mechanisms and Immune-Based Biomarkers of Drug-Induced Liver Injury
por: Liu, Wenhui, et al.
Publicado: (2021)